⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALMS News
Alumis Inc. Common Stock
Form 8-K
sec.gov
ALMS
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
globenewswire.com
ALMS
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
globenewswire.com
ALMS
Alumis to Present at the Leerink Partners Global Healthcare Conference
globenewswire.com
ALMS
Alumis to Participate in Upcoming February Investor Conferences
globenewswire.com
ALMS
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
ALMS
Alumis Announces Pricing of Upsized Public Offering of Common Stock
globenewswire.com
ALMS
Alumis Announces Proposed Public Offering of Common Stock
globenewswire.com
ALMS